The economic returns of pediatric clinical trials of anti-hypertensive drugs

BACKGROUND: Congress has authorized the U.S. Food and Drug Administration (FDA) to provide industry sponsors with a 6-month extension of drug marketing rights under the Pediatric Exclusivity Provision if FDA-requested pediatric drug trials are conducted. The cost and economic return of pediatric exc...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Baker-Smith, Carissa M., Benjamin, Daniel K., Grabowski, Henry G., Reid, Elizabeth D., Mangum, Barry, Goldsmith, John V., Murphy, M. Dianne, Edwards, Rex, Eisenstein, Eric L., Sun, Jessica, Califf, Robert M., Li, Jennifer S.
Format: Artigo
Jezik:Inglês
Izdano: 2008
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3334305/
https://ncbi.nlm.nih.gov/pubmed/18926149
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ahj.2008.05.001
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki